3OCT

CEPI awards Minapharm US$16.5m for Ebola

2 min read

13:42UTC

CEPI awarded up to US$16.5m on 27 August to Egypt's Minapharm and its Berlin subsidiary ProBioGen to take a Bundibugyo vaccine into a first trial in people.

← Back to River boat carries Ebola 1,000 km downriver Jump to analysis ↓

ScienceDeveloping

Key takeaway

CEPI's fifth Bundibugyo vaccine candidate is planned for full manufacture in Cairo.

The Coalition for Epidemic Preparedness Innovations (CEPI), which funds vaccines against outbreak threats, awarded up to US$16.5m on 27 August to Egypt's Minapharm and its Berlin subsidiary ProBioGen⁠¹. The money takes an MVA-vectored candidate against Bundibugyo ebolavirus, the Ebola species behind DR Congo's outbreak, into a Phase 1 trial in Africa. MVA is a weakened pox virus engineered to carry another pathogen's proteins, and a Phase 1 trial is a first small test of safety in people.

CEPI called it its fifth Bundibugyo-specific candidate. The fourth, on the rVSV platform, received US$1.9m for seed stock in June, and the first entered trial production at the end of July.

Drug substance will be made in Berlin and the finished doses in Cairo, with a technology transfer planned so that Cairo can make the whole vaccine. Jean Kaseya of Africa CDC said: "A vaccine candidate advanced by an African company is exactly the kind of capability our continent needs." A Phase 1 study cannot show whether a vaccine protects, so this award builds African manufacturing for the next Bundibugyo outbreak more than it changes the course of this one.

Deep Analysis

In plain English

There is no approved vaccine for the type of Ebola now spreading in DR Congo, called Bundibugyo. Moderna, Oxford University and others have at least five candidates in development. CEPI, the Coalition for Epidemic Preparedness Innovations, pays for early vaccine research. It has given up to US$16.5m to Minapharm, an Egyptian drug company, and its German subsidiary ProBioGen. The money pays for a first small trial in Africa to check the vaccine is safe. The goal is for the vaccine to be made in Cairo eventually, so Africa does not have to wait for supplies from Europe, America or India in the next outbreak.

Deep Analysis

Root Causes

Bundibugyo vaccine work starts almost from scratch because the species causes outbreaks rarely, so no commercial buyer exists between them. Every candidate depends on CEPI or government grants, and each outbreak restarts the clock.

Africa's main vaccine-making gap, as of 2026, lies in drug substance, the active ingredient. Minapharm's plan reflects that: ProBioGen will make the drug substance in Berlin at first, and Cairo will only fill and finish until technology transfer completes.

CEPI's split bets follow from the science. Its earlier US$4.17m went to testing whether Zaire-species vaccines cross-protect , because no one yet knows which immune response protects against Bundibugyo.

What could happen next?

Opportunity
A Cairo plant able to make the full vaccine would give the African Union's health agency a supplier inside the continent for future Bundibugyo outbreaks.
Long term · Suggested
Consequence
Minapharm's Phase 1 is unlikely to produce data in time to change the course of the 2026 outbreak.
Short term · Assessed
Risk
If Moderna or Oxford reaches efficacy first, demand for a fifth candidate may vanish, repeating the idle-capacity problem of 2022.
Medium term · Suggested

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: In June 2021 WHO launched an mRNA technology-transfer hub at Afrigen in Cape Town to give African manufacturers their own COVID-19 vaccine know-how. The hub produced its own mRNA vaccine at laboratory scale in 2022, but no African-made COVID-19 vaccine reached mass use before demand collapsed.

Counter-parallel: South Africa's Aspen Pharmacare finished Johnson & Johnson's COVID-19 vaccine in Gqeberha from 2021 and later won a licence to sell it in Africa under its own brand. In 2022 Aspen said it had received no orders, because donated doses had filled the market; local capacity without guaranteed buyers stood idle.

At up to US$16.5m, the award is small next to CEPI's US$196m Ebola pledge listed by Africa CDC. Phase 1 trials are cheap; the expensive steps are Phase 3 and the plant scale-up that follows.

For Minapharm the value lies in the platform. The MVA-CR19 vector, grown in ProBioGen's duck cell line, can be reused for other pathogens, so a working Cairo plant would give Egypt a base for future outbreak vaccines beyond Ebola.

Consensus view: CEPI says the Minapharm design is its only Bundibugyo candidate built to raise both antibody (B-cell) and T-cell responses, and Africa CDC's Jean Kaseya calls an African-made candidate 'exactly the kind of capability our continent needs'. The case rests on supply: a vaccine finished in Cairo would not queue behind orders from richer buyers.

Counter-view: The Independent in Kampala lists faster rivals: Moderna's mRNA-1469 in Phase 1 in Canada since early August and Oxford's ChAdOx1 candidate, made with the Serum Institute of India, in Phase 1 since July. By that measure the outbreak needs the candidate nearest to efficacy data, and Minapharm has not yet dosed anyone.

Key tension: Whether funding a slower African-made candidate buys supply security for the next Bundibugyo outbreak at the cost of speed in this one.

First Reported In

Update #14 · River boat carries Ebola 1,000 km downriver

CEPI· 3 Oct 2026

Read original →

Causes and effects

Caused by

CEPI puts a Bundibugyo vaccine in trials

CEPI added a fifth Bundibugyo candidate after putting its first into trial production in July.

Occurred 31 Jul 2026

Read story →

$4.17m to test Zaire vaccine antibodies

CEPI's August cross-reactivity awards were followed a week later by funding for a species-matched candidate.

Occurred 19 Aug 2026

Read story →

This Event

CEPI awards Minapharm US$16.5m for Ebola

The award adds a fifth Bundibugyo-specific vaccine candidate and plans to move its full manufacture to Cairo.

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.